ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Fact-checker says critics misrepresented 'chestfeeding' after CDC controversy

Fact-checker PolitiFact argued critics had misrepresented "chestfeeding" after the CDC was ripped for offering advice on how transgender parents can "chestfeed."

Fact-checking media outlet PolitiFact defended the controversial term "chestfeeding" after the Centers for Disease Control was criticized for publishing guidance on how transgender parents can "chestfeed" their infants.

PolitiFact argued medical professionals who accused the health agency of giving dangerous advice had "misrepresented what chestfeeding is, how the term is used and raised fears over medications involved in induced lactation."

The outlet defended the term "chestfeeding" as more inclusive to transgender men, who may have had their breasts removed but still want to feed their infants. 

"These parents, who were pregnant and had a baby, may also want to nurse their newborn infants but prefer a word other than breastfeeding.' The term may cause gender dysphoria, which can exacerbate mental health challenges such as anxiety and depression," the article reads.

The fact-checker also cited studies suggesting that milk produced by drugs and hormone therapies was the same quality as milk naturally produced by mothers.

CDC GIVES GUIDANCE FOR TRANS PEOPLE ‘CHESTFEEDING’ KIDS, ACCUSED OF FAILING TO CONSIDER POSSIBLE HEALTH RISKS

"The development of mammary glands and breast tissue can occur in trans women who take estrogen and progesterone as a part of hormone replacement therapy," PolitiFact wrote. Dr. Casey Rosen-Carole, chief of the Division of Breastfeeding & Lactation Medicine at the University of Rochester School of Medicine, told the outlet that one study showed that mammary tissue in transgender women who have taken hormones can be "as well organized for milk production as someone who was assigned female at birth."

The fact-checker also pushed back on criticism from medical professionals who argued that lactation-inducing drugs could be passed along in the milk and be dangerous for infants.

Earlier this month, U.S. Sen. Roger Marshall, who served as an obstetrician for 25 years, slammed the government health agency after its advice on how transgender parents who've had breast surgery "can breastfeed or chestfeed their infants," went viral.

Marshall accused the CDC of placing "politics and its social agenda ahead of science and the health of newborns," saying their advice endorsed anti-nausea medication Domperidone, "a risky drug not legally approved or sold in the U.S.," to induce milk production.

MEDIA CONTINUE TO TOUT DOCTORS DEFENDING TRANSGENDER TREATMENTS FOR CHILDREN IN CBS INTERVIEW

The Daily Mail also spoke to several doctors who noted there are health risks with this drug, and they pose uncertain long-term health risks to the infant.

Dr. Stuart Fischer, a New York-based internal medicine physician, told the Daily Mail that it is "very hard to believe" that the breast milk naturally-occurring in a biological female is the same as the breast milk induced in a biological man. 

He is also noted it is uncertain how the latter form of breast milk would affect infants, asking, "If it's been tested a handful of times, how would we know the long-range effect? The short-term is one thing, but the long-term in terms of physical and mental illness..."

"It's an emerging field, to put it mildly," Fischer added. 

PolitiFact addressed these concerns by pointing out that the CDC website did not explicitly endorse this drug, but says transgender "families may need help with…medication to induce lactation or avoiding medications that inhibit lactation." The organization denied "endorsing using drugs to induce lactation" in a statement to the media outlet.

PolitiFact's article also cited a case study published this year on the NIH website which reportedly found a transgender woman was able to produce milk as "nutritionally adequate and co-equal to milk produced by cis-gender women." However, the case study reported this effect was achieved through using the very FDA-banned drug, Domperidone, that some doctors had warned about. 

The CDC did not immediately respond to a request for comment.

For more Culture, Media, Education, Opinion, and channel coverage, visit foxnews.com/media.

Fox News' Gabriel Hays contributed to this report.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.